查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095378

中樞神經系統治療市場－2026-2032年全球市場預測

Central Nervous System Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，中樞神經系統治療市場將成長至 2,535.4 億美元，複合年成長率為 7.54%。

主要市場統計數據
基準年 2025 1523.3億美元
預計年份：2026年 1635.2億美元
預測年份 2032 2535.4億美元
複合年成長率 (%) 7.54%

中樞神經系統（CNS）療法包括用於治療神經系統和精神疾病的藥物和先進療法，例如阿茲海默症、帕金森氏思覺失調症、癲癇、多發性硬化症、憂鬱症、憂鬱症、精神分裂症、神經病變症、神經性疼痛以及罕見的神經遺傳性疾病。神經系統疾病負擔日益加重、人口老化、診斷能力的提升、人們對心理健康意識的增強以及精準神經病學、神經免疫學和神經精神病學領域的快速創新，正在推動這一領域的變革。全球衛生機構的數據顯示，神經系統疾病一直被認為是全球範圍內導致殘疾和健康損害的主要原因，而失智症、中風相關損傷、癲癇、偏頭痛和情緒障礙等疾病仍然給醫療保健系統帶來巨大的臨床和社會經濟負擔。同時，由於血腦障壁挑戰、疾病生物學異質性、臨床試驗週期長、精神病學研究中安慰劑效應高以及對高靈敏度生物標記的需求等因素，中樞神經系統藥物的研發在科學上仍然十分複雜。產業重點正轉向疾病修正治療、早期療育、患者分層、數位化終點、真實世界數據以及整合診斷、治療依從性、復健、看護者支持和長期監測的綜合護理路徑。對於藥物研發、生物技術、臨床研究、保險公司策略和醫療服務領域的相關人員，當前中樞神經系統治療的現狀需要系統性地關注檢驗的作用機制、有意義的臨床結果、監管協調以及患者公平獲得治療的機會。

中樞神經系統治療領域的變革性變化

隨著治療研發從對症治療轉向標靶、生物學驅動的主導，中樞神經系統治療格局正在改變性轉變。在神經退化性疾病領域，澱粉樣蛋白、 Tau蛋白、α-突觸核蛋白、神經發炎、溶小體功能、粒線體生物學和遺傳風險路徑等的研究進展，使得更具針對性的臨床計畫得以開展；同時，腦脊髓液分析、神經影像學、腦電圖和血液生物標記的引入，也提高了患者篩選和疾病分期的準確性。在精神醫學領域，創新已超越傳統的單胺類神經傳導物質療法，拓展至麩胺酸調節、神經可塑性路徑、晝夜節律生物學、發炎相關機制以及針對難治性疾病的快速起效療法。癲癇和偏頭痛的治療表明，基於機制的研發可以透過更精準地靶向離子通道、神經肽和突觸訊號傳導來改善治療效果。監管預期也在發生變化，更加重視具有臨床意義的終點指標、檢驗生物標記的使用、長期安全性監測、上市後證據以及納入多樣化的患者群體。醫療服務模式正轉向多學科協作模式，整合神經科醫生、精神科醫生、基層醫療醫生、看護者、復健專家和數位監測工具。這些變化凸顯了在整個產品生命週期中產生證據的重要性，涵蓋轉化科學、適應性臨床試驗設計、藥物安全性監測、用藥依從性支持以及醫療技術評估等各個方面。

人工智慧對中樞神經系統治療的累積影響

人工智慧正透過改善研究人員發現標靶、分類患者、設計試驗和監測結果的方式，對整個中樞神經系統治療領域產生累積影響。在藥物發現階段，機器學習模型被應用於基因組學、蛋白質組學、轉錄組學、影像學、電生理學和臨床資料集，以識別疾病相關路徑並預測化合物特性，包括中樞神經系統滲透性和毒性風險。在臨床開發階段，人工智慧可輔助最佳化方案、選擇臨床實驗、篩檢合格、在適當情況下考慮合成對照組，以及識別具有特徵性進展模式的患者亞群。自然語言處理有助於建立臨床記錄和患者報告訊息，而電腦視覺和訊號分析則擴展了源自磁振造影(MRI)、正子斷層掃描 (PET)、腦電圖 (EEG)、語音分析、步態分析、睡眠數據和效用裝置的數位生物標記的應用價值。這些功能在阿茲海默症、帕金森氏症、多發性硬化症、癲癇、憂鬱症和神經發育障礙等疾病中尤其重要，因為這些疾病的病程具有異質性，且傳統終點指標難以反映病情變化。然而，將人工智慧引入中樞神經系統（CNS）治療必須以數據品質、透明度、減少偏差、保護隱私、監管檢驗和臨床可解釋性為基礎。其最有效的應用在於輔助專家臨床判斷，提高可重複性，並產生能夠經得起科學界、監管機構和保險公司審查的證據。

關於中樞神經系統療法的關鍵區域見解

在亞太地區，人口老化、專科醫生數量增加以及人們對精神健康和神經退化性疾病負擔日益成長的認知，推動了對改善診斷和治療可及性的需求，進一步提升了該地區在中樞神經系統治療領域的重要性。儘管該地區各國都在投資醫院基礎設施、臨床研究網路、失智症治療和數位健康平台，但主要都市區和農村地區之間的醫療資源取得仍然存在差距。在歐洲，協調的監管體系、國家衛生技術評估流程、強大的神經科學學術網路以及對失智症、精神健康、多發性硬化症、癲癇和罕見神經系統疾病日益成長的政策關注，都是其優勢所在。北美仍然是中樞神經系統治療創新領域的高度已開發地區，這得益於成熟的神經科學研究機構、臨床試驗基礎設施、專業醫療保健網路、患者支持活動以及促進循證醫學發展的監管路徑，這些都為滿足高度未滿足的需求領域提供了支持。在非洲，由於專科醫生數量有限、診斷存在缺口、藥物獲取困難、與衝突相關的心理健康需求以及社會歧視等原因，神經系統和精神疾病的治療存在大量未滿足的需求。然而，遠距遠端醫療、基本藥物計劃、癲癇管理、人力資源開發以及將心理健康更廣泛地納入基層醫療保健環境。在中東，透過對三級醫療機構、醫療旅遊中心、數位醫療系統和國家醫療保健轉型計劃的投資，中樞神經系統醫療保健正在得到加強，但人力資源開發、確保醫療服務的連續性以及解決不同收入水平和地理位置之間的醫療服務獲取差距等挑戰依然存在。

關於中樞神經系統治療的關鍵小組見解

北約成員國擁有許多高標準的醫療保健系統，人們對腦健康、創傷性腦損傷、創傷後壓力症候群（PTSD）、神經復健和心理健康韌性的關注度日益提高，尤其關注現役軍人、退伍軍人、緊急應變人員以及暴露於危機相關壓力源的普通民眾。七國集團（G7）透過資助前沿研究、監管科學、真實世界數據（RWE）生成、罕見疾病框架、老化政策以及在神經病學和精神病學領域採用精準醫療方法，持續對中樞神經系統（CNS）治療標準的製定發揮重要作用。歐盟透過統一的藥品監管、跨境研究合作、藥物安全監測系統、歐洲參考網路以及強調比較臨床療效、安全性和成本效益的衛生技術評估（HTA）框架，為中樞神經系統治療提供了一個系統的環境。金磚國家擁有大規模的患者群體、不斷擴展的臨床試驗能力和日益增強的國內製藥能力，但在保險報銷、都市區醫療資源獲取、專科醫生分佈和診斷基礎設施方面存在顯著差異，導致中樞神經系統（CNS）治療格局呈現多樣性。東南亞國協正透過醫療現代化、擴大保險覆蓋範圍、加強區域監管合作以及日益關注中風、癲癇、失智症、憂鬱症和神經發育障礙等疾病，來擴大中樞神經系統治療的覆蓋範圍，但成本效益和專科醫生短缺仍然是重要的限制因素。海灣合作理事會（GCC）國家正透過大力投資醫療體系、建立三級神經病學中心、引入數位醫療、制定以慢性病管理、精神健康和專業復健為重點的國家戰略，以及日益關注與衰老和代謝性疾病相關的神經系統併發症，來推進中樞神經系統治療。在全部區域，政策協調、數據互通性、擴大醫療團隊、循證報銷和公平獲取醫療資源是改善中樞神經系統治療效果的關鍵。

主要國家中樞神經系統治療趨勢

美國是中樞神經系統（CNS）治療研究、專科醫療服務、先進診斷技術和患者支持領域的領先中心，積極參與神經退化性疾病、精神病學、癲癇、偏頭痛、多發性硬化症和罕見神經系統疾病的治療。中國在人口老化、中風負擔加重、失智症認知度提高以及精神衛生改革的背景下，正迅速擴大其中樞神經系統研究能力、醫院神經科服務和診斷技術應用。德國以其先進的醫院基礎設施、專科神經科服務、強大的臨床研究能力和嚴格的醫保報銷審核系統為循證中樞神經系統治療的推廣提供了支持。日本人口老化迅速，且擁有完善的專科醫療基礎設施，在老齡化相關神經系統疾病、失智症護理、帕金森氏症和先進診斷技術方面擁有深厚的專業知識。印度面臨著癲癇、中風相關疾病、感染疾病、失智症、偏頭痛和精神疾病等沉重的疾病負擔，這為提供可負擔的治療、遠距神經病學、數位心理健康以及與基層醫療的整合提供了巨大的機會。英國擁有強大的神經科學生態系統，其背後有國家臨床指南、學術研究、健康數據資產和數位健康舉措的支持，政策重點關注失智症、憂鬱症和嚴重精神疾病。法國已建立神經系統疾病照護網路，並正在加強其公共衛生工作，以應對神經退化性疾病和精神疾病。同時，加拿大將公共資助的醫療保健服務與積極的神經科學研究相結合，並日益關注失智症護理、心理健康服務以及解決原住民的健康差距問題。澳洲強調以指南為基礎的中樞神經系統 (CNS) 護理、心理健康政策、數位健康服務和神經復健。同時，義大利和西班牙繼續加強在其社區醫療保健系統中對失智症護理、多發性硬化症服務、癲癇管理和心理健康的整合。韓國擁有強大的醫療資訊基礎設施，正積極推動神經科學研究、醫院技術、失智症政策和數位療法的整合。俄羅斯神經病學和精神病學領域整體中樞神經系統（CNS）治療的需求非常高，但醫療服務的可及性取決於區域基礎設施、醫療專業人員的分佈以及國家醫療政策的優先事項。巴西人口眾多、老化嚴重、癲癇盛行率高、精神健康需求旺盛，且公共和私人醫療管道不斷擴張，因此對中樞神經系統治療的需求也極高，但區域間醫療服務可近性差異仍顯著。墨西哥雖然神經病學和精神病學的醫療能力正在不斷提升，但專科醫生資源、診斷工具的可用性以及保險報銷方面的差異，阻礙了新型中樞神經系統療法的引入。

為中樞神經系統治療領域的領導者提供的實用建議

中樞神經系統治療領域的產業領導者應優先考慮利用生物檢驗標靶、患者分層策略和生物標記來提高獲得具有臨床意義的療效的研發計劃。臨床計畫應從研發早期階段納入多樣化的病患群體招募、可操作的終點選擇、與看護者相關的結局指標、功能評估、安全性監測和真實世界資料（RWE）規劃。各機構應投資於轉化神經科學能力建設，將分子生物學、影像學、電生理學、數位生物標記和縱向臨床資料集結合。與學術機構、醫院、病患團體和技術提供者建立夥伴關係，可以在不影響科學嚴謹性的前提下，提高受試者招募率、藥物依從性、數據品質、試驗多樣性和上市後證據的產生。應儘早制定准入策略，明確闡述臨床價值、安全性監測要求、給藥物流、診斷前提條件以及對醫療保健系統的影響。對於神經退化性疾病疾病和罕見神經系統疾病，相關人員應做好準備，建立必要的基礎設施，以支持早期診斷途徑、生物標記檢測、靜脈注射和特殊給藥、必要的遺傳諮詢以及長期監測。在精神科領域，領導者必須將藥物依從性、共病、社會歧視、復發預防和持續照護作為治療成功的核心要素。在所有中樞神經系統 (CNS) 疾病類別中，負責任的人工智慧 (AI)管治、網路安全、監管合規和透明的模型檢驗必須融入營運模式。永續的進展取決於將創新與可衡量的患者獲益、可負擔性、醫療服務提供者的準備情況以及公平的醫療服務獲取途徑相結合。

中樞神經系統藥物分析的調查方法

本執行摘要採用系統性的二手調查方法編寫，重點關注與中樞神經系統治療相關的、檢驗的、公開可用的資訊來源。研究方法包括對同行評審的醫學文獻、臨床實踐指南、監管出版刊物、公共衛生資料庫、疾病負擔評估、臨床試驗註冊庫、藥物安全監測資源、衛生技術評估文件以及權威衛生機構發布的政策出版刊物進行審查。目標疾病領域涵蓋神經病學、精神病學、神經免疫學、神經退化性疾病、疼痛醫學、癲癇、運動障礙、神經發育障礙和罕見中樞神經系統疾病。透過檢視醫療基礎設施、診斷能力、專科醫生資源、報銷機制、人口趨勢、研究活動和公共衛生優先事項，整合了區域和國家層面的見解。調查方法強調對可靠資訊來源進行檢驗，以避免依賴單一資訊來源，並排除未經證實的預測、市場規模估算、市場佔有率和商業性預測。透過定性分析，我們識別出一些反覆出現的主題，例如生物標記的引入、人工智慧（AI）的應用、臨床試驗的現代化、監管預期、醫療服務取得方面的差異以及整合式醫療模式。我們從醫療產業的觀點解讀這些發現，旨在為參與中樞神經系統（CNS）藥物研發、醫學事務、醫療政策和醫療服務等相關人員提供策略決策支持，同時確保事實的準確性、中立性和相關性。

結論：中樞神經系統（CNS）治療藥物的未來發展方向

中樞神經系統（CNS）治療正處於關鍵的轉折點，其特點是科學進步、未被滿足的需求以及證明其具有實際臨床價值的壓力日益增加。生物標記、基因組學、影像學、數位測量、神經免疫學和人工智慧的進步正在提高我們理解疾病機制、篩選合適患者和監測治療反應的能力。同時，該領域仍面臨著許多挑戰，包括疾病複雜的生物學特性、高研發風險​​、治療機會不均、精神健康污名化、專科醫生短缺以及許多地區診斷基礎設施不平衡。區域、人群和國家層面的差異表明，中樞神經系統治療的成功不僅取決於創新，還取決於診斷能力、報銷體系、人力資源發展、循證標準以及以患者為中心的醫療服務模式。整合嚴謹的神經科學、負責任的資料科學、全面的臨床研究和公平的醫療服務取得方案的相關人員將更有能力應對神經和精神疾病帶來的疾病負擔。中樞神經系統 (CNS) 療法的未來將由那些能夠展現持續療效、融入真實世界臨床護理路徑並改善患者、看護者、臨床醫生和整個醫療保健系統結果的療法所塑造。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 中樞神經系統治療藥物市場：依藥物類別分類

  • 抗憂鬱症
  • 抗精神病藥物
  • 抗驚厥藥物
  • 抗焦慮藥物
  • 麻醉劑
  • 止痛藥
  • 中樞神經系統興奮劑

第8章 中樞神經系統治療市場：依疾病適應症分類

  • 神經退化性疾病
    • 阿茲海默症
    • 帕金森氏症
    • 亨丁頓舞蹈症
    • 多發性硬化症
  • 精神疾病
    • 重度憂鬱症
    • 焦慮症
    • 思覺失調症
    • 躁鬱症
  • 神經血管疾病
    • 中風
    • 腦動脈瘤
  • 中樞神經系統創傷
    • 創傷性腦損傷（TBI）
    • 脊髓損傷

第9章 中樞神經系統治療藥物市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 經皮給藥

第10章 中樞神經系統治療藥物市場：依作用機轉分類

  • 基因治療
  • 單株抗體
  • 胜肽
  • 低分子化合物

第11章 中樞神經系統治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第12章 中樞神經系統治療市場：依分銷管道分類

  • 物理藥房
  • 網路藥房

第13章 中樞神經系統治療市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 非洲
  • 拉丁美洲
  • 中東

第14章 中樞神經治療市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第15章 中樞神經系統治療市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 印度
  • 英國
  • 法國
  • 加拿大
  • 澳洲
  • 義大利
  • 韓國
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • AC Immune SA
  • Acadia Pharmaceuticals, Inc.
  • Alkermes plc
  • Amgen Inc.
  • Anavex Life Sciences Corp.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • H. Lundbeck A/S
  • Ipsen SA
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Neumora Therapeutics, Inc.
  • Neurocrine Biosciences, Inc.
  • Neurona Therapeutics Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
Product Code: MRR-02026C4C9A19

The Central Nervous System Therapeutics Market is projected to grow by USD 253.54 billion at a CAGR of 7.54% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 152.33 billion
Estimated Year [2026] USD 163.52 billion
Forecast Year [2032] USD 253.54 billion
CAGR (%) 7.54%

Central nervous system therapeutics encompass medicines and advanced treatment approaches for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, migraine, depression, schizophrenia, anxiety disorders, neuropathic pain, and rare neurogenetic conditions. The field is being reshaped by the rising burden of neurological disorders, aging populations, improved diagnostic capabilities, expanded mental health awareness, and accelerated innovation in precision neurology, neuroimmunology, and neuropsychiatry. Data from global health authorities consistently identify neurological conditions as a leading contributor to disability and ill health worldwide, while dementia, stroke-related impairment, epilepsy, migraine, and mood disorders continue to create substantial clinical and socioeconomic pressure on healthcare systems. At the same time, central nervous system drug development remains scientifically complex due to blood-brain barrier challenges, heterogeneous disease biology, long trial durations, high placebo response in psychiatric studies, and the need for sensitive biomarkers. Industry priorities are shifting toward disease-modifying therapies, earlier intervention, patient stratification, digital endpoints, real-world evidence, and integrated care pathways that connect diagnosis, treatment adherence, rehabilitation, caregiver support, and long-term monitoring. For stakeholders across pharmaceutical development, biotechnology, clinical research, payer strategy, and healthcare delivery, the central nervous system therapeutics landscape requires a disciplined focus on validated mechanisms, meaningful clinical outcomes, regulatory alignment, and equitable patient access.

Transformative Shifts in the CNS Therapeutics Landscape

The central nervous system therapeutics landscape is undergoing transformative shifts as treatment development moves beyond symptomatic relief toward targeted, biology-led intervention. In neurodegenerative diseases, advances in amyloid, tau, alpha-synuclein, neuroinflammation, lysosomal function, mitochondrial biology, and genetic risk pathways are enabling more focused clinical programs, while the adoption of cerebrospinal fluid assays, neuroimaging, electroencephalography, and blood-based biomarkers is improving patient selection and disease staging. In psychiatry, innovation is expanding beyond traditional monoamine-based approaches to include glutamatergic modulation, neuroplasticity pathways, circadian biology, inflammation-linked mechanisms, and rapid-acting therapies for treatment-resistant conditions. The epilepsy and migraine treatment areas illustrate how mechanism-based development can improve outcomes through more precise targeting of ion channels, neuropeptides, and synaptic signaling. Regulatory expectations are also evolving, with greater emphasis on clinically meaningful endpoints, validated biomarker use, long-term safety monitoring, post-authorization evidence, and inclusion of diverse patient populations. Healthcare delivery is shifting toward multidisciplinary models that integrate neurologists, psychiatrists, primary care providers, caregivers, rehabilitation specialists, and digital monitoring tools. These changes are elevating the importance of evidence generation across the full product lifecycle, from translational science and adaptive clinical trial design to pharmacovigilance, adherence support, and health technology assessment.

Cumulative Impact of Artificial Intelligence in CNS Therapeutics

Artificial intelligence is creating cumulative impact across central nervous system therapeutics by improving how researchers discover targets, classify patients, design trials, and monitor outcomes. In discovery, machine learning models are being applied to genomics, proteomics, transcriptomics, imaging, electrophysiology, and clinical datasets to identify disease-relevant pathways and predict compound properties, including central nervous system penetration and toxicity risk. In clinical development, artificial intelligence supports protocol optimization, site selection, eligibility screening, synthetic control exploration where appropriate, and detection of patient subgroups with distinct progression patterns. Natural language processing can help structure clinical notes and patient-reported information, while computer vision and signal analytics are expanding the utility of magnetic resonance imaging, positron emission tomography, electroencephalography, speech analysis, gait analysis, sleep data, and wearable-derived digital biomarkers. These capabilities are particularly relevant in Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, depression, and neurodevelopmental conditions, where disease trajectories are heterogeneous and conventional endpoints may be slow to change. However, artificial intelligence adoption in CNS therapeutics must be governed by data quality, transparency, bias mitigation, privacy protection, regulatory validation, and clinical interpretability. The strongest applications are those that complement expert clinical judgment, improve reproducibility, and generate evidence that can withstand scientific, regulatory, and payer scrutiny.

Key Regional Insights Across CNS Therapeutics

Asia-Pacific is becoming increasingly important in central nervous system therapeutics as aging demographics, expanding specialist capacity, and growing recognition of mental health and neurodegenerative disease burden drive demand for improved diagnosis and treatment access. Countries across the region are investing in hospital infrastructure, clinical research networks, dementia strategies, and digital health platforms, although access remains uneven between major urban centers and rural populations. Europe benefits from coordinated regulatory systems, national health technology assessment processes, strong academic neuroscience networks, and increasing policy attention to dementia, mental health, multiple sclerosis, epilepsy, and rare neurological conditions. North America remains a highly advanced environment for CNS therapeutic innovation, supported by established neuroscience research institutions, clinical trial infrastructure, specialty care networks, patient advocacy activity, and regulatory pathways that encourage evidence-based development in areas of high unmet need. Africa faces significant unmet need in neurological and psychiatric care due to limited specialist density, diagnostic gaps, medicine availability constraints, conflict-related mental health needs, and stigma, yet opportunities are emerging through telemedicine, essential medicines programs, epilepsy initiatives, workforce training, and broader integration of mental health into primary care. Latin America presents a complex CNS care environment shaped by expanding public health coverage, increasing neurological disease recognition, and persistent disparities in specialist availability, diagnostic imaging, rehabilitation services, and access to newer medicines. The Middle East is strengthening CNS care through investments in tertiary hospitals, medical tourism hubs, digital health systems, and national health transformation programs, while still addressing workforce development, continuity-of-care challenges, and access variation across income groups and geographies.

Key Group Insights for CNS Therapeutics

NATO member countries overlap with many high-capacity healthcare systems and are increasingly attentive to brain health, traumatic brain injury, post-traumatic stress disorder, neurorehabilitation, and mental health resilience, particularly for active-duty personnel, veterans, emergency responders, and civilian populations exposed to crisis-related stressors. The G7 remains influential in shaping CNS therapeutic standards through advanced research funding, regulatory science, real-world evidence generation, rare disease frameworks, aging policy, and adoption of precision medicine approaches in neurology and psychiatry. The European Union provides a structured environment for CNS therapeutics through harmonized medicines regulation, cross-border research collaboration, pharmacovigilance systems, European reference networks, and health technology assessment frameworks that emphasize comparative clinical benefit, safety, and cost-effectiveness. BRICS countries collectively represent diverse CNS treatment environments, with large patient populations, expanding clinical trial capacity, growing domestic pharmaceutical capabilities, and significant variation in reimbursement, urban-rural access, specialist distribution, and diagnostic infrastructure. ASEAN countries are expanding central nervous system therapeutic access through healthcare modernization, broader insurance coverage, regional regulatory cooperation, and growing attention to stroke, epilepsy, dementia, depression, and neurodevelopmental disorders, although affordability and specialist shortages remain important constraints. The GCC is advancing CNS care through high-investment health systems, tertiary neurology centers, digital health adoption, national strategies focused on chronic disease management, mental health, and specialized rehabilitation, and growing attention to neurological complications associated with aging and metabolic disease. Across these groups, policy alignment, data interoperability, workforce expansion, evidence-based reimbursement, and equitable access are central to improving CNS treatment outcomes.

Key Country Insights in CNS Therapeutics

The United States is a leading center for central nervous system therapeutic research, specialty care delivery, advanced diagnostics, and patient advocacy, with strong activity in neurodegenerative disease, psychiatry, epilepsy, migraine, multiple sclerosis, and rare neurological disorders. China is rapidly expanding CNS research capacity, hospital-based neurology services, and diagnostic adoption, driven by aging demographics, stroke burden, dementia recognition, and mental health reform. Germany is characterized by advanced hospital infrastructure, specialty neurology services, clinical research strength, and rigorous reimbursement assessment, supporting evidence-based adoption of CNS therapeutics. Japan has deep expertise in aging-related neurological disease, dementia care, Parkinson's disease, and advanced diagnostics, supported by a rapidly aging population and established specialist infrastructure. India faces a high burden of epilepsy, stroke-related disability, neuroinfections, dementia, migraine, and psychiatric disorders, with major opportunities in affordable treatment, tele-neurology, digital mental health, and primary-care integration. The United Kingdom maintains a strong neuroscience ecosystem supported by national clinical guidelines, academic research, health data assets, and digital health initiatives, with policy attention to dementia, depression, and severe mental illness. France has established neurological care networks and strong public health engagement in neurodegenerative and psychiatric disorders, while Canada combines publicly funded healthcare access with active neuroscience research and growing emphasis on dementia strategies, mental health services, and indigenous health equity. Australia emphasizes guideline-based CNS care, mental health policy, digital health access, and neurological rehabilitation, while Italy and Spain continue to strengthen dementia care, multiple sclerosis services, epilepsy management, and mental health integration within regional health systems. South Korea is advancing neuroscience research, hospital technology, dementia policy, and digital therapeutics integration, supported by strong health information infrastructure. Russia has significant CNS treatment needs across neurology and psychiatry, with access shaped by regional infrastructure, workforce distribution, and domestic healthcare priorities. Brazil has substantial demand for CNS therapies due to population scale, aging, epilepsy prevalence, mental health needs, and expanding public and private care pathways, though regional access differences remain significant. Mexico is expanding neurological and psychiatric care capacity, while disparities in specialist access, diagnostic availability, and reimbursement influence adoption of newer CNS treatments.

Actionable Recommendations for CNS Therapeutics Leaders

Industry leaders in central nervous system therapeutics should prioritize biologically validated targets, patient stratification strategies, and biomarker-enabled development plans to improve the probability of clinically meaningful outcomes. Clinical programs should incorporate diverse patient populations, pragmatic endpoint selection, caregiver-relevant outcomes, functional measures, safety surveillance, and real-world evidence planning from early development onward. Organizations should invest in translational neuroscience capabilities that connect molecular biology, imaging, electrophysiology, digital biomarkers, and longitudinal clinical datasets. Partnerships with academic centers, hospitals, patient organizations, and technology providers can strengthen recruitment, adherence, data quality, trial diversity, and post-approval evidence generation without compromising scientific rigor. Access strategies should be designed early, with clear articulation of clinical value, safety monitoring requirements, administration logistics, diagnostic prerequisites, and health system impact. For neurodegenerative and rare neurological diseases, stakeholders should prepare for earlier diagnosis pathways and the infrastructure required for biomarker testing, infusion or specialty administration, genetic counseling where appropriate, and long-term monitoring. In psychiatry, leaders should address adherence, comorbidity, stigma, relapse prevention, and care continuity as core components of therapeutic success. Across all CNS categories, responsible artificial intelligence governance, cybersecurity, regulatory compliance, and transparent model validation should be embedded in operating models. Sustainable progress will depend on aligning innovation with measurable patient benefit, affordability, provider readiness, and equitable access.

Research Methodology for CNS Therapeutics Analysis

This executive summary is developed using a structured secondary research methodology focused on verified, publicly available, and evidence-based sources relevant to central nervous system therapeutics. The research approach includes review of peer-reviewed medical literature, clinical practice guidelines, regulatory publications, public health databases, disease burden assessments, clinical trial registries, pharmacovigilance resources, health technology assessment documents, and policy publications from recognized health authorities. Disease-area evaluation covers neurology, psychiatry, neuroimmunology, neurodegeneration, pain medicine, epilepsy, movement disorders, neurodevelopmental disorders, and rare CNS conditions. Regional and country-level insights are synthesized by examining healthcare infrastructure, diagnostic capacity, specialist access, reimbursement frameworks, demographic trends, research activity, and public health priorities. The methodology emphasizes triangulation across credible sources to avoid reliance on single-point claims and excludes unsupported projections, market sizing, market share, and commercial forecasting. Qualitative analysis is applied to identify recurring themes such as biomarker adoption, artificial intelligence use, clinical trial modernization, regulatory expectations, access disparities, and integrated care models. Findings are interpreted through a healthcare industry lens to support strategic decision-making while maintaining factual accuracy, neutrality, and relevance for stakeholders in CNS drug development, medical affairs, health policy, and care delivery.

Conclusion: Future Direction of CNS Therapeutics

Central nervous system therapeutics are entering a pivotal period defined by scientific progress, unmet patient need, and increasing pressure to demonstrate meaningful clinical value. Advances in biomarkers, genomics, imaging, digital measurement, neuroimmunology, and artificial intelligence are improving the ability to identify disease mechanisms, select appropriate patients, and monitor therapeutic response. At the same time, the field continues to face persistent challenges, including complex disease biology, high development risk, variable treatment access, stigma surrounding mental health, limited specialist availability, and uneven diagnostic infrastructure in many regions. Regional, group, and country-level differences show that CNS therapeutic success depends not only on innovation but also on diagnostic capacity, reimbursement readiness, workforce development, evidence standards, and patient-centered delivery models. Stakeholders that integrate rigorous neuroscience, responsible data science, inclusive clinical research, and equitable access planning will be better positioned to address neurological and psychiatric disease burden. The future of CNS therapeutics will be shaped by therapies that can prove durable benefit, fit real-world care pathways, and improve outcomes for patients, caregivers, clinicians, and healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Central Nervous System Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Antidepressants
  • 7.3. Antipsychotics
  • 7.4. Anticonvulsants
  • 7.5. Anxiolytics
  • 7.6. Anesthetics
  • 7.7. Pain Relievers
  • 7.8. CNS Stimulants

8. Central Nervous System Therapeutics Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Neurodegenerative Disorders
    • 8.2.1. Alzheimer's Disease
    • 8.2.2. Parkinson's Disease
    • 8.2.3. Huntington's Disease
    • 8.2.4. Multiple Sclerosis
  • 8.3. Psychiatric Disorders
    • 8.3.1. Major Depressive Disorder
    • 8.3.2. Anxiety Disorders
    • 8.3.3. Schizophrenia
    • 8.3.4. Bipolar Disorder
  • 8.4. Neurovascular Diseases
    • 8.4.1. Stroke
    • 8.4.2. Cerebral Aneurysm
  • 8.5. CNS Trauma
    • 8.5.1. Traumatic Brain Injury (TBI)
    • 8.5.2. Spinal Cord Injury

9. Central Nervous System Therapeutics Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Transdermal

10. Central Nervous System Therapeutics Market, by Mechanism Of Action

  • 10.1. Introduction
  • 10.2. Gene Therapy
  • 10.3. Monoclonal Antibodies
  • 10.4. Peptides
  • 10.5. Small Molecules

11. Central Nervous System Therapeutics Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Home Care
  • 11.4. Hospitals

12. Central Nervous System Therapeutics Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline Pharmacies
  • 12.3. Online Pharmacies

13. Central Nervous System Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Africa
  • 13.5. Latin America
  • 13.6. Middle East

14. Central Nervous System Therapeutics Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. ASEAN
  • 14.6. GCC

15. Central Nervous System Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. China
  • 15.3. Germany
  • 15.4. Japan
  • 15.5. India
  • 15.6. United Kingdom
  • 15.7. France
  • 15.8. Canada
  • 15.9. Australia
  • 15.10. Italy
  • 15.11. South Korea
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. AC Immune SA
  • 17.3. Acadia Pharmaceuticals, Inc.
  • 17.4. Alkermes plc
  • 17.5. Amgen Inc.
  • 17.6. Anavex Life Sciences Corp.
  • 17.7. Biogen Inc.
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Eli Lilly and Company
  • 17.10. F. Hoffmann-La Roche Ltd.
  • 17.11. GSK plc
  • 17.12. H. Lundbeck A/S
  • 17.13. Ipsen S.A.
  • 17.14. Jazz Pharmaceuticals plc
  • 17.15. Johnson & Johnson
  • 17.16. Merck & Co., Inc.
  • 17.17. Neumora Therapeutics, Inc.
  • 17.18. Neurocrine Biosciences, Inc.
  • 17.19. Neurona Therapeutics Inc.
  • 17.20. Novartis AG
  • 17.21. Otsuka Pharmaceutical Co., Ltd.
  • 17.22. Pfizer Inc.
  • 17.23. PTC Therapeutics, Inc.
  • 17.24. Sanofi S.A.
  • 17.25. Sumitomo Pharma Co., Ltd.
  • 17.26. Supernus Pharmaceuticals, Inc.
  • 17.27. Takeda Pharmaceutical Company Limited
  • 17.28. Teva Pharmaceutical Industries Ltd.
  • 17.29. UCB S.A.
  • 17.30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIPSYCHOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPSYCHOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPSYCHOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANESTHETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANESTHETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANESTHETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PAIN RELIEVERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PAIN RELIEVERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PAIN RELIEVERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CNS STIMULANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CNS STIMULANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CNS STIMULANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUNTINGTON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUNTINGTON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUNTINGTON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MAJOR DEPRESSIVE DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MAJOR DEPRESSIVE DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MAJOR DEPRESSIVE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANXIETY DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANXIETY DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANXIETY DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STROKE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STROKE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STROKE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CEREBRAL ANEURYSM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CEREBRAL ANEURYSM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CEREBRAL ANEURYSM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CNS TRAUMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CNS TRAUMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CNS TRAUMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRAUMATIC BRAIN INJURY (TBI) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRAUMATIC BRAIN INJURY (TBI) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRAUMATIC BRAIN INJURY (TBI) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 199. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 243. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 244. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 246. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 275. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 286. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 287. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 288. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 289. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 291. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE CENT